For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, VYNE Therapeutics Inc’s stock clocked out at $0.29, down -2.54% from its previous closing price of $0.3. In other words, the price has decreased by -$2.54 from its previous closing price. On the day, 1.56 million shares were traded. VYNE stock price reached its highest trading level at $0.3053 during the session, while it also had its lowest trading level at $0.2915.
Ratios:
To gain a deeper understanding of VYNE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 7427693 and an Enterprise Value of -32194316. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.47 while its Price-to-Book (P/B) ratio in mrq is 0.15. Its current Enterprise Value per Revenue stands at -67.635.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.90, which has changed by -0.8463158 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is -63.45%, while the 200-Day Moving Average is calculated to be -83.27%.
Shares Statistics:
It appears that VYNE traded 2.19M shares on average per day over the past three months and 1812720 shares per day over the past ten days. A total of 25.47M shares are outstanding, with a floating share count of 20.82M. Insiders hold about 18.25% of the company’s shares, while institutions hold 27.66% stake in the company. Shares short for VYNE as of 1755216000 were 2115574 with a Short Ratio of 0.97, compared to 1752537600 on 333476. Therefore, it implies a Short% of Shares Outstanding of 2115574 and a Short% of Float of 8.36.
Earnings Estimates
The current assessment of VYNE Therapeutics Inc (VYNE) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.89 and -$0.89 for the fiscal current year, implying an average EPS of -$0.89. EPS for the following year is -$1.1, with 1.0 analysts recommending between -$1.1 and -$1.1.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $100k. It ranges from a high estimate of $100k to a low estimate of $100k. As of the current estimate, VYNE Therapeutics Inc’s year-ago sales were $121kFor the next quarter, 1 analysts are estimating revenue of $100k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is $100k.